Is alteplase (t-PA) more cost-effective than streptokinase?
Sanchez
L A
LA
Brigham and Women's Hospital, Boston, Massachusetts.
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004341:Drug Evaluation; D006801:Humans; D017059:Models, Econometric; D009203:Myocardial Infarction / Q000188:drug therapy; D013300:Streptokinase / Q000191:economics / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000191:economics / Q000627:therapeutic use